Tenax Therapeutics to Discuss Second Quarter 2016 Financial Results and Provide Business Update

MORRISVILLE, N.C.--()--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will host a conference call and live audio webcast on Thursday, August 11, 2016, at 8:30 a.m. ET to discuss its second quarter 2016 financial results and provide a business update.

To participate in the call, please dial 877-407-8029 (domestic) or 201‐689‐8029 (international) and refer to conference ID 13642237. A live webcast of the call can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.tenaxthera.com. An archived webcast recording will be available on the Tenax Therapeutics website beginning approximately two hours after the call.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The Company is currently enrolling a Phase 3 trial with levosimendan in that indication, and is also supporting Imperial College London’s LeoPARDS trial for levosimendan in septic shock. For more information, visit www.tenaxthera.com.

Contacts

Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com

Release Summary

Tenax Therapeutics, Inc. (NASDAQ: TENX) to host conference call and live audio webcast on Aug. 11, 2016, at 8:30 a.m. ET to discuss its 2nd quarter 2016 financial results and provide a business update

Contacts

Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com